• Yi-Hui Li, Yang Zhou, Guang-Ju Zhang, Yu-Wei Wang, Jian-Gong Wang, Xiao-Hong Wang, and Yu-Feng Li.
• Department of Chemoradiotherapy, Tangshan People's Hospital, Tangshan, Hebei Province, China.
• Medicine (Baltimore). 2022 Sep 9; 101 (36): e30239e30239.

RationaleVulvar melanoma is a rare and aggressive tumor with a high risk of local recurrence and distant metastasis. The prognosis is poor with a 5-year overall survival rate of only 46.6%. Management of vulvar melanoma remains a clinical challenge. Recent evidences have shown that immune checkpoint inhibitors are effective in the treatment of vulvar melanoma.Patient Concerns And DiagnosesA 63-year-old woman with vulvar malignant melanoma suffered inguinal lymph node metastasis after vulvectomy and chemotherapy. She underwent inguinal lymph node dissection and inguinal radiotherapy. The tumor progressed again and she received immunotherapy.InterventionsThe tumor progressed again, and she was admitted to our hospital and received toripalimab combined with apatinib and abraxane.OutcomesAfter 6 cycles of immunotherapy, the efficacy achieved partial remission. And with toripalimab as maintenance therapy, the patient achieved durable antitumor efficacy and good safety.LessonsIn this rare case, the patient with metastatic vulvar malignant melanoma had durable antitumor efficacy and good safety when receiving toripalimab.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

14 keywords...

hide…